GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 2seventy bio Inc (NAS:TSVT) » Definitions » Piotroski F-Score

2seventy bio (2seventy bio) Piotroski F-Score : 5 (As of May. 11, 2024)


View and export this data going back to 2021. Start your Free Trial

What is 2seventy bio Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

2seventy bio has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for 2seventy bio's Piotroski F-Score or its related term are showing as below:

TSVT' s Piotroski F-Score Range Over the Past 10 Years
Min: 5   Med: 5   Max: 5
Current: 5

During the past 6 years, the highest Piotroski F-Score of 2seventy bio was 5. The lowest was 5. And the median was 5.


2seventy bio Piotroski F-Score Historical Data

The historical data trend for 2seventy bio's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

2seventy bio Piotroski F-Score Chart

2seventy bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial N/A N/A N/A 5.00 5.00

2seventy bio Quarterly Data
Dec18 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 N/A 4.00 4.00 5.00

Competitive Comparison of 2seventy bio's Piotroski F-Score

For the Biotechnology subindustry, 2seventy bio's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


2seventy bio's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 2seventy bio's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where 2seventy bio's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -47.021 + -42.089 + -71.638 + -56.822 = $-217.6 Mil.
Cash Flow from Operations was -49.088 + -32.663 + -21.512 + -63.595 = $-166.9 Mil.
Revenue was 41.621 + 36.048 + 12.034 + 10.684 = $100.4 Mil.
Gross Profit was 37.326 + 31.531 + 7.075 + 7.537 = $83.5 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(656.665 + 742.437 + 705.713 + 640.806 + 565.426) / 5 = $662.2094 Mil.
Total Assets at the begining of this year (Dec22) was $656.7 Mil.
Long-Term Debt & Capital Lease Obligation was $244.0 Mil.
Total Current Assets was $237.8 Mil.
Total Current Liabilities was $59.8 Mil.
Net Income was -85.711 + -77.42 + -67.879 + -23.143 = $-254.2 Mil.

Revenue was 8.429 + 13.482 + 13.408 + 56.177 = $91.5 Mil.
Gross Profit was -0.8 + 4.946 + 9.447 + 51.684 = $65.3 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(759.675 + 851.921 + 787.406 + 708.744 + 656.665) / 5 = $752.8822 Mil.
Total Assets at the begining of last year (Dec21) was $759.7 Mil.
Long-Term Debt & Capital Lease Obligation was $259.0 Mil.
Total Current Assets was $300.9 Mil.
Total Current Liabilities was $79.8 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

2seventy bio's current Net Income (TTM) was -217.6. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

2seventy bio's current Cash Flow from Operations (TTM) was -166.9. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-217.57/656.665
=-0.33132571

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-254.153/759.675
=-0.33455491

2seventy bio's return on assets of this year was -0.33132571. 2seventy bio's return on assets of last year was -0.33455491. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

2seventy bio's current Net Income (TTM) was -217.6. 2seventy bio's current Cash Flow from Operations (TTM) was -166.9. ==> -166.9 > -217.6 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=244.013/662.2094
=0.36848314

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=259.008/752.8822
=0.34402195

2seventy bio's gearing of this year was 0.36848314. 2seventy bio's gearing of last year was 0.34402195. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=237.765/59.779
=3.97740009

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=300.882/79.794
=3.77073464

2seventy bio's current ratio of this year was 3.97740009. 2seventy bio's current ratio of last year was 3.77073464. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

2seventy bio's number of shares in issue this year was 51.406. 2seventy bio's number of shares in issue last year was 38.712. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=83.469/100.387
=0.8314722

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=65.277/91.496
=0.71344102

2seventy bio's gross margin of this year was 0.8314722. 2seventy bio's gross margin of last year was 0.71344102. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=100.387/656.665
=0.15287399

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=91.496/759.675
=0.12044098

2seventy bio's asset turnover of this year was 0.15287399. 2seventy bio's asset turnover of last year was 0.12044098. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+0+1+0+1+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

2seventy bio has an F-score of 5 indicating the company's financial situation is typical for a stable company.

2seventy bio  (NAS:TSVT) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


2seventy bio Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of 2seventy bio's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


2seventy bio (2seventy bio) Business Description

Traded in Other Exchanges
N/A
Address
60 Binney Street, Cambridge, MA, USA, 02142
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.
Executives
Nick Leschly director, officer: President and CEO C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Philip D Gregory officer: Chief Scientific Officer POINT RICHMOND TECH CENTER II, 501 CANAL BOULEVARD SUITE A100, RICHMOND CA 94804
Baird William D Iii officer: Chief Financial Officer C/O BLUEBIRD BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142
Yue Tang 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Kynam Fund Gp, Llc 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Kynam Global Healthcare Master Fund, Lp 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Kynam Capital Management Gp, Llc 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Kynam Capital Management, Lp 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Lin Wei director C/O ERASCA, INC., 10835 ROAD TO THE CURE, SUITE 140, SAN DIEGO CA 92121
Nicola Heffron officer: Chief Operating Officer 2SEVENTY BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142
Marcela V. Maus director 16 RICHMOND CIRCLE, LEXINGTON MA 02421
Ramy Ibrahim director C/O SURFACE ONCOLOGY, 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Sarah Js Glickman director 60 BINNEY STREET, C/O BLUEBIRD BIO, INC., CAMBRIDGE MA 02142
Daniel Lynch director
Denice Torres director 3 RABBIT RUN DRIVE, NEW HOPE PA 18938